Cross-border biotech collaborations between China and the U.S. are becoming increasingly intricate, with a potential slowdown anticipated due to expanding U.S. restrictions on investments and technology transfers. Despite this, analysts suggest that the trend of Western pharmaceutical companies partnering with Chinese firms will endure, spurred by China’s rising innovation, with the value of out-licensing agreements expected to reach $240 billion in 2026, up from $136 billion in 2025. Only major pharmaceutical companies are likely to navigate these regulatory challenges effectively, maintaining their prominence in future transactions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/us-china-biotech-deals-face-slowdown-amid-expanding-restrictions/
